PAVmed Announces Early 2027 Veris Submission and Medicare Reimbursement for Lucid's EsoGuard
PAVmed (PAVM) reported significant progress across its product portfolio during its Q3 2026 management update. A major milestone was achieved by Lucid, which successfully secured Medicare reimbursement for the EsoGuard device, a development described by CEO Lishan Aklog as transformational for the company. Additionally, the company outlined its regulatory roadmap, targeting an early 2027 submission for the Veris 510(k) clearance. These developments signal progress in both commercialization through reimbursement and long-term product pipeline advancement.
Tickers: $PAVM
Topics: Medicare reimbursement Product milestone Q3 Earnings Call